Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on Health & Wellness Today New York.
Press releases published on June 23, 2025
NetraMark's AI Significantly Outperforms ChatGPT, DeepSeek and Traditional Machine Learning in Clinical Trial Subpopulation Discovery, Offers New Path for Trial Success
GlobeNewswire
·
June 23, 2025
TORONTO, June 23, 2025 (GLOBE NEWSWIRE) -- NetraMark Holdings Inc. (the “Company” or “NetraMark”) (CSE: AIAI) (OTCQB: AINMF) (Frankfurt: PF0) a premier artificial intelligence (AI) company that is transforming clinical trials has released a new preprint on …
NeuroOne® Patient Surpasses One Year Milestone of Seizure Freedom Following Treatment with OneRF® Ablation System
GlobeNewswire
·
June 23, 2025
Patient Treated with OneRF® Ablation System Previously Experienced up to 10 Seizures a Day EDEN PRAIRIE, Minn., June 23, 2025 (GLOBE NEWSWIRE) -- NeuroOne Medical Technologies Corporation (Nasdaq: NMTC) ("NeuroOne" or the "Company"), a medical technology …
Sienna Senior Living Expands in the Greater Toronto Area
GlobeNewswire
·
June 23, 2025
MARKHAM, Ontario, June 23, 2025 (GLOBE NEWSWIRE) -- Sienna Senior Living Inc. (“Sienna” or the “Company”) (TSX: SIA) announced today that it has entered into a purchase agreement to acquire Credit River Retirement Residence, a 133-suite retirement …
New Data Presented at ADA 2025 Highlights Burden and Risk Associations of Cardiac Arrhythmias in Patients with Type 2 Diabetes and Chronic Kidney Disease
GlobeNewswire
·
June 23, 2025
SAN FRANCISCO, June 23, 2025 (GLOBE NEWSWIRE) -- iRhythm Technologies, Inc. (NASDAQ:IRTC) announced the results from two large-scale real-world studies presented at the American Diabetes Association’s 85th Scientific Sessions (ADA 2025). The analyses …
Biomarkers Market worth US$104.15 billion in 2030 with 10.8% CAGR | MarketsandMarkets™.
GlobeNewswire
·
June 23, 2025
Delray Beach, FL, June 23, 2025 (GLOBE NEWSWIRE) -- The global biomarkers market, valued at US$58.07 billion in 2024 stood at US$62.39 billion in 2025 and is projected to advance at a resilient CAGR of 10.8% from 2025 to 2030, culminating in a forecasted …
Eyenovia Announces Closing of $50 Million Private Placement, Successful Accumulation of More Than One Million HYPE Tokens, and Update on its Optejet Development Program
GlobeNewswire
·
June 23, 2025
The significant HYPE token position, acquired at an average price of approximately $34 per token, makes Eyenovia the first Nasdaq listed company to run a validator on Hyperliquid FDA registration of the Optejet User Filled Device (UFD) on track for …
BioStem Technologies Completes Enrollment in Clinical Trial Evaluating BioREtain® Amnion Chorion for Treatment of Diabetic Foot Ulcers
GlobeNewswire
·
June 23, 2025
Head-to-head study comparing BioREtain®- processed Amnion Chorion (BR-AC) allograft to standard of care initiated in Q4 2024 to demonstrate healing superiority Topline results and full data analysis expected in Q4 2025 POMPANO BEACH, Fla., June 23, 2025 ( …
Emergent BioSolutions Secures $62.4 Million Contract Modification for BAT® [Botulism Antitoxin Heptavalent (A, B, C, D, E, F, G) – (Equine)] to Bolster U.S. Biodefense Supply
GlobeNewswire
·
June 23, 2025
GAITHERSBURG, Md., June 23, 2025 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) today announced it has been awarded a $62.4 million contract modification from the Administration for Strategic Preparedness and Response (ASPR), a division of the …
NKGen Biotech Announces International and U.S. Expansion of Phase 1/2a Troculeucel Alzheimer’s Trial with Activation of Clinical Sites in Canada and Florida
GlobeNewswire
·
June 23, 2025
SANTA ANA, Calif., June 23, 2025 (GLOBE NEWSWIRE) -- NKGen Biotech, Inc. (OTC: NKGN) (“NKGen” or the “Company”), a clinical-stage biotechnology company focused on the development and commercialization of innovative autologous and allogeneic natural killer …
Candel Therapeutics Appoints Charles Schoch as Chief Financial Officer
GlobeNewswire
·
June 23, 2025
NEEDHAM, Mass., June 23, 2025 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical-stage biopharmaceutical company focused on developing multimodal biological immunotherapies to help patients fight cancer, today …
Firefly Neuroscience to be Added to the Russell Microcap® Index
GlobeNewswire
·
June 23, 2025
– Comes less than a year after listing on Nasdaq – KENMORE, N.Y., June 23, 2025 (GLOBE NEWSWIRE) -- Firefly Neuroscience, Inc. (“Firefly” or the “Company”) (NASDAQ: AIFF), an Artificial Intelligence (“AI”) company developing innovative solutions that …
Ashvattha Therapeutics Reports the Ability to Tune Nanomedicines to Image Neuroinflammation in Multiple Sclerosis Patients and Tumor Associated Macrophages in Cancer at SNMMI Annual Meeting
GlobeNewswire
·
June 23, 2025
Novel nanomedicine radiotracer crosses blood brain barrier in patients with neuroinflammation Tumor macrophage radiotracer achieves 41.6% peak tumor uptake in preclinical studies REDWOOD CITY, Calif., June 23, 2025 (GLOBE NEWSWIRE) -- Ashvattha …
Ajay Dhankhar joins Smith+Nephew as Chief Corporate Development & Strategy Officer
GlobeNewswire
·
June 23, 2025
Smith+Nephew (LSE:SN, NYSE:SNN), the global medical technology company, announces the appointment of Ajay Dhankhar, PhD, as Chief Corporate Development …
MBX Biosciences Appoints Andreas Moraitis, M.D., as Senior Vice President of Clinical Development
GlobeNewswire
·
June 23, 2025
CARMEL, Ind., June 23, 2025 (GLOBE NEWSWIRE) -- MBX Biosciences, Inc. (Nasdaq: MBX), a clinical-stage biopharmaceutical company focused on the discovery and development of novel precision peptide therapies for the treatment of endocrine and metabolic …
Chiesi Global Rare Diseases Awards Research Grants to Advance Innovation in Lysosomal Diseases
GlobeNewswire
·
June 23, 2025
PARMA, Italy, June 23, 2025 (GLOBE NEWSWIRE) -- Chiesi Global Rare Diseases, a business unit of the Chiesi Group established to deliver innovative therapies and solutions for people living with rare diseases, today announced the recipients of its "Find For …
Optime Care Partners with Tilde Sciences as Exclusive Specialty Pharmacy Provider for Vecamyl
GlobeNewswire
·
June 23, 2025
ST. LOUIS, June 23, 2025 (GLOBE NEWSWIRE) -- Optime Care, AscellaHealth’s Specialty Pharmacy, is pleased to announce an expanded partnership with Tilde Sciences LLC (“Tilde”), effective June 23, 2025. Under this arrangement, Optime Care will serve as the …
Data Demonstrating Sotagliflozin Reduces the Risk of Clinically Important Hypoglycemic Events in Adults with Type 1 Diabetes When Added to Insulin Presented at the 85th Scientific Sessions of the American Diabetes Association (ADA)
GlobeNewswire
·
June 23, 2025
Oral presentation highlighted the post-hoc analysis during the “Interventions to Prevent Hypoglycemia: Bench to Bedside” session Treatment with sotagliflozin resulted in no increased risk and a reduction in hypoglycemia events, particularly in patients …
ORYZON Announces Submission of Phase III Protocol to FDA to Initiate PORTICO-2 Trial of Vafidemstat in Borderline Personality Disorder (BPD) Patients
GlobeNewswire
·
June 23, 2025
PORTICO-2 designed to validate vafidemstat’s efficacy in reducing aggression in BPD patients Primary endpoint: STAXI-2 Trait Anger (patient-reported) Key secondary endpoint: Overt Aggression Scale-Modified (OAS-M) (clinician-rated) Additional secondary …
RAPT Therapeutics Names Two Industry Veterans to its Board of Directors
GlobeNewswire
·
June 23, 2025
SOUTH SAN FRANCISCO, Calif., June 23, 2025 (GLOBE NEWSWIRE) -- RAPT Therapeutics, Inc. (Nasdaq: RAPT), a clinical-stage immunology-based biopharmaceutical company focused on discovering, developing and commercializing novel therapies for patients living …
AnswersNow CEO and Founder Jeff Beck Named EY Entrepreneur of the Year®2025 Mid-Atlantic Award Winner
GlobeNewswire
·
June 23, 2025
RICHMOND, Va., June 23, 2025 (GLOBE NEWSWIRE) -- AnswersNow, the leader in virtual Applied Behavioral Analysis (ABA) therapy, today announced that Ernst …